|Bid||17.50 x 900|
|Ask||20.49 x 900|
|Day's Range||19.42 - 20.57|
|52 Week Range||15.21 - 69.57|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.17|
G1 THERAPEUTICS (GTHX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
From Iqvia to Red Hat to Xerium Technologies, executives and investors at top Triangle firms raked in millions by selling shares in 2018, U.S. Securities and Exchange Commission filings show.
RESEARCH TRIANGLE PARK, N.C., Dec. 27, 2018 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
G1 Therapeutics Inc (NASDAQ: GTHX ) reported positive top-line results Wednesday for its Phase 2 trilaciclib trial in small cell lung cancer. What Happened The candidate met primary endpoints in reducing ...
G1 Therapeutics Inc. shares dropped in the extended session Wednesday after the biotech drug maker said one of its drugs met endpoints in a clinical study but had not done as well as other metrics versus a placebo treatment. G1 Therapeutics shares, which had been halted after hours, fell 24% after closing up 0.9% at $28.75 in regular trading. The company said a mid-stage clinical trial showed that the use of its drug trilaciclib with another cancer drug in small-cell lung cancer patients significantly reduced the duration and instances of Grade 4 neutropenia, or a low white blood cell count which can result in infections. On the other hand, the company also reported that in other metrics, the treatment was less effective than in patients given a placebo treatment. G1 said patients given the treatment had an "objective response rate" of 13.3% versus 23.1% in the placebo group, and a "clinical benefit rate" of 60% versus 61.5% in the placebo group. "We now have four randomized Phase 2 trials showing trilaciclib's multi-lineage myelopreservation benefits," said Raj Malik, G1 chief medical officer, in a statement. "We plan to meet with U.S. and European regulatory authorities in 2019 to discuss the totality of trilaciclib data and pathways to approval."
Achieved both primary endpoints: statistically significant reductions in the duration and occurrence of Grade 4 neutropeniaClinically meaningful reductions in rates of.
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Patients on trilaciclib received more chemotherapy cycles than those in the control armTrilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...
Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in first-line small cell lung cancer (1L.
G1 Therapeutics, Inc. (GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized Phase 2 clinical trial of trilaciclib in combination with chemotherapy for the treatment of metastatic triple-negative breast cancer (mTNBC) have been selected for a poster discussion Spotlight Session presentation on December 5, 2018 at the 2018 San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas. "Metastatic triple-negative breast cancer is difficult to treat.
Positive data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer presented at ESMO 2018 highlight myelopreservation and immune system.
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2018 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 18.) Boston Scientific Corporation (NYSE: BSX ) Cara Therapeutics ...